These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8429292)

  • 1. An epidemiologic perspective on biomarkers.
    Schatzkin A; Freedman L; Schiffman M
    J Intern Med; 1993 Jan; 233(1):75-9. PubMed ID: 8429292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surrogate end points in cancer research: a critique.
    Schatzkin A; Freedman LS; Dorgan J; McShane LM; Schiffman MH; Dawsey SM
    Cancer Epidemiol Biomarkers Prev; 1996 Dec; 5(12):947-53. PubMed ID: 8959315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Problems with using biomarkers as surrogate end points for cancer: a cautionary tale.
    Schatzkin A
    Recent Results Cancer Res; 2005; 166():89-98. PubMed ID: 15648185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of intermediate end points in cancer research.
    Schatzkin A; Freedman LS; Schiffman MH; Dawsey SM
    J Natl Cancer Inst; 1990 Nov; 82(22):1746-52. PubMed ID: 2231769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermediate markers as surrogate endpoints in cancer research.
    Schatzkin A
    Hematol Oncol Clin North Am; 2000 Aug; 14(4):887-905. PubMed ID: 10949779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoprevention trials and surrogate end point biomarkers in the cervix.
    Mitchell MF; Hittelman WK; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Wharton JT; Hong WK
    Cancer; 1995 Nov; 76(10 Suppl):1956-77. PubMed ID: 8634987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using and interpreting surrogate end-points in cancer research.
    Schatzkin A; Freedman LS; Dorgan J; McShane L; Schiffman MH; Dawsey SM
    IARC Sci Publ; 1997; (142):265-71. PubMed ID: 9354925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermediate effect markers for colorectal cancer.
    Baron JA
    IARC Sci Publ; 2001; 154():113-29. PubMed ID: 11220651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining environmental exposure and genetic effect measurements in health outcome assessment.
    Bonassi S
    Mutat Res; 1999 Jul; 428(1-2):177-85. PubMed ID: 10517991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The promise and peril of surrogate end points in cancer research.
    Schatzkin A; Gail M
    Nat Rev Cancer; 2002 Jan; 2(1):19-27. PubMed ID: 11902582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporating biomarkers into cancer epidemiology: a matrix of biomarker and study design categories.
    Rothman N; Stewart WF; Schulte PA
    Cancer Epidemiol Biomarkers Prev; 1995 Jun; 4(4):301-11. PubMed ID: 7655323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity.
    Stearns V; Gallagher A; Kleer CG; Singh B; Freedman M; Haddad BR; Isaacs C; Warren R; Brown M; Cullen J; Trock B; Hayes DF
    Clin Cancer Res; 2004 Dec; 10(24):8332-40. PubMed ID: 15623610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk biomarkers and current strategies for cancer chemoprevention.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample size for studying intermediate endpoints within intervention trails or observational studies.
    Freedman LS; Schatzkin A
    Am J Epidemiol; 1992 Nov; 136(9):1148-59. PubMed ID: 1462974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers in occupational cancer epidemiology: considerations in study design.
    Hayes RB
    Environ Health Perspect; 1992 Nov; 98():149-54. PubMed ID: 1486844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can biomarkers help us understand the nutritional and lifestyle factors important in cancer prognosis?
    Schatzkin A
    J Nutr; 2007 Jan; 137(1 Suppl):249S-252S. PubMed ID: 17182835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human somatic mutation assays as biomarkers of carcinogenesis.
    Compton PJ; Hooper K; Smith MT
    Environ Health Perspect; 1991 Aug; 94():135-41. PubMed ID: 1954924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.
    Collette L; Burzykowski T; Carroll KJ; Newling D; Morris T; Schröder FH; ; ;
    J Clin Oncol; 2005 Sep; 23(25):6139-48. PubMed ID: 16135480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
    Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
    Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.